Chief executive of AstraZeneca
Appears in 1 story
Led AstraZeneca through the Enhertu development and UK pricing agreement
England's drug assessment body NICE approved Enhertu for HER2-low advanced breast cancer on September 17, reversing a rejection that had stood since July 2024. About 1,000 women a year become eligible, and the treatment extended median overall survival by 6.6 months in the pivotal trial.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
